Omalizumab - An effective and safe treatment of therapy-resistant chronic spontaneous urticaria

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue 2, 2011, Pages 303-305

  Groffik, A ^b   Mitzel Kaoukhov, H ^b   Magerl, M ^b   Maurer, M ^b   Staubach, P ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b NONE

Author keywords

angioedema; IgE; immunotherapy; urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DAPSONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB;

ADULT; AGED; ANGIONEUROTIC EDEMA; BLOOD PRESSURE; CHRONIC SPONTANEOUS URTICARIA; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOTHERAPY; INTERMITTENT HEADA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PRURITUS; REMISSION; SHORT SURVEY; SIDE EFFECT; TREATMENT RESPONSE; URTICARIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; URTICARIA; YOUNG ADULT;

EID: 78651096597     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.02472.x     Document Type: Short Survey

References (5)

1. 2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
2. Staubach P, Eckhardt-Henn A, Dechene M, Vonend A, Metz M, Magerl M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006; 154: 294-298.
3. 2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
4. Spector SL, Tan RA,. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007; 99: 190-193.
5. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK,. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122: 569-573.